ストックスクリーナーアプリを入手
27.07
1.17%
-0.32
前日終値:
$27.39
開ける：
$27.12
24時間の取引高:
234.99K
Relative Volume:
1.56
時価総額：
$912.18M
収益：
-
当期純損益:
$-81.05M
株価収益率:
-10.32
EPS:
-2.6232
ネットキャッシュフロー:
$-68.97M
1週間 パフォーマンス:
+1.77%
1か月 パフォーマンス:
+6.95%
6か月 パフォーマンス:
+13.17%
1年 パフォーマンス:
+36.17%
1日の値動き範囲:
$26.61
$27.84
1週間の範囲:
$25.89
$28.12
52週間の値動き範囲:
$14.35
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
AVBP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
27.07 | 912.18M | 0 | -81.05M | -68.97M | -2.6232 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-22 | 開始されました | Oppenheimer | Outperform |
| 2024-04-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-02-20 | 開始されました | Citigroup | Buy |
| 2024-02-20 | 開始されました | Goldman | Buy |
| 2024-02-20 | 開始されました | Jefferies | Buy |
Arrivent Biopharma Inc (AVBP) 最新ニュース
Where are the Opportunities in (AVBP) - Stock Traders Daily
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Update - MarketBeat
Mirae Asset Global Investments Co. Ltd. Makes New Investment in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Mirae Asset Global Investments Co. Ltd. Purchases Shares of 1,123 ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Armenian Reporter
How To Trade (AVBP) - Stock Traders Daily
Short Interest in ArriVent BioPharma, Inc. (NASDAQ:AVBP) Expands By 13.1% - MarketBeat
Deal Watch: Novo Nordisk, IMMvention To Partner On Sickle Cell Disease - News & Insights
Asia’s NewCo Model, FDA tipping point, Vertex’s pain drug: a BioCentury podcast - BioCentury
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Bought by JPMorgan Chase & Co. - Defense World
(AVBP) Trading Signals - Stock Traders Daily
Abbvie seeks molecular glue degraders from Neomorph - BioCentury
ArriVent in Newtown Square Sees Big Potential in New Cancer Drug - DELCO.Today
ArriVent BioPharma Secures Global Rights to MRG007 in Strategic Deal with Lepu Biopharma - MSN
Lepu Biopharma’s $1.6 Billion ADC Licensing Agreement with ArriVent Biopharma - Global Legal Chronicle
Equities Analysts Set Expectations for AVBP Q1 Earnings - Defense World
HC Wainwright Issues Positive Estimate for AVBP Earnings - MarketBeat
More China ADCs: Arrivent gets GI cancer drug in $1.2B Lepu deal - BioWorld Online
ArriVent Biopharma price target raised to $39 from $36 at H.C. Wainwright - Yahoo Finance
ArriVent Biopharma enters license agreement with Lepu Biopharma - MSN
Cancer Biotech ArriVent Lands an ADC for GI Malignancies and Makes Best-in-Class Claim - MedCity News
Intellia makes progress on HAE study; 2 more China drug deals - BioPharma Dive
ArriVent inks ADC licensing deal with Lepu Biopharma - The Pharma Letter
ArriVent bets big on experimental cancer drug with potential $1B licensing deal - The Business Journals
Arrivent Biopharma licenses ex-China rights to Lepu’s ADC for gastrointestinal cancers - BioWorld Online
ArriVent Joins Chinese Licensing Trend With Potential $1.2B+ ADC Deal with Lepu - BioSpace
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers - The Manila Times
Lepu Biopharma has granted ArriVent Exclusive License for MRG007, a Potential Best-in-Class ADC for the - Digital More
Lepu Biopharma has granted ArriVent Exclusive License for MRG007, a Potential Best-in-Class ADC for the treatment of Gastrointestinal Cancers - The Manila Times
Lepu Biopharma Co., Ltd. Enters into an Exclusive Licensing Agreement with Arrivent Biopharma, Inc - Marketscreener.com
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma - WICZ
Lepu Biopharma Grants Exclusive License for Novel ADC MRG007 to ArriVent - TipRanks
ArriVent BioPharma Secures Global Rights to Promising Cancer Drug MRG007 in $1.2B Deal - StockTitan
(AVBP) Investment Analysis - Stock Traders Daily
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Up 13.1% in December - MarketBeat
Windtree Therapeutics Secures Patent in Japan for Cancer Treatment Platform - MyChesCo
ArriVent BioPharma (NASDAQ:AVBP) Shares Gap DownWhat's Next? - MarketBeat
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Barclays PLC Has $976,000 Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Biopharma IPOs rebound slightly, as class of 2024 lags with a 29% average decline - BioWorld Online
Jane Street Group LLC Has $250,000 Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
We're Not Very Worried About ArriVent BioPharma's (NASDAQ:AVBP) Cash Burn Rate - Simply Wall St
ArriVent BioPharma (NASDAQ:AVBP) Trading Down 5%Should You Sell? - MarketBeat
Geode Capital Management LLC Increases Stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Barclays PLC Increases Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Stock Position Increased by Geode Capital Management LLC - MarketBeat
Barclays PLC Buys 38,132 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
(AVBP) Proactive Strategies - Stock Traders Daily
State Street Corp Acquires 323,186 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - MarketBeat
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Stake Lifted by State Street Corp - Defense World
Arrivent Biopharma Inc (AVBP) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):